Why Jim Cramer Likes Allergan
Allergan (AGN) - Get Report is such a good pharmaceutical play that Jim Cramer, who already owns the name in his charitable trust, plans to buy even shares more if the stock pulls back from here.
"Here's a company with a 9% increase in revenues that sells more cheaply than all of the other major pharmas. That makes no sense to me, especially given all the approvals in [Allergen's pipeline]," Cramer said in an exclusive call with members of his Action Alerts PLUS club for investors.
Want to join in on Jim's monthly conference calls? Click here for a free 14-day trial subscription to Action Alerts PLUS and hear all of the latest call, plus get e-mails before Jim makes any trade and enjoy lots of other exclusive material.
More of What's Trending on TheStreet:
- Bitcoin's Getting Hard to Ignore, Even for Wall Street Titan Goldman Sachs
- The Price of Trump's 'Locked & Loaded': The 10 Costliest Wars in U.S. History
- These 11 Cars Embarrassingly Lose Half Their Value in Three Years
- Here Are 30 of Nike's Most Iconic and Expensive Sneakers
Watch More with TheStreet:
- Say Hello to the Next Gold Rush: Cryptocurrency Miners Are Showing Off Insane Rigs on Instagram
- Gary Cohn Is Not a Good Choice for Federal Reserve Chair, Barney Frank Warns
- Apple, Microsoft and Cisco Are Holding Almost $500 Billion Overseas
- The 5 Most Expensive Wars In American History
Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long AGN.
